Title:
SUBSTITUTED CYCLOPENTANES AS CDK2 INHIBITORS
Document Type and Number:
WIPO Patent Application WO/2023/168686
Kind Code:
A1
Abstract:
The present disclosure provides a compound represented by structural formula (I) : or a pharmaceutically acceptable salt, or a stereoisomer thereof and their use in, e.g. treating a disease or disorder associated with CDK2. This disclosure also features compositions containing the same as well as methods of using and making the same.
Inventors:
LI HAILONG (CN)
HE HU (CN)
ZHONG WENGE (CN)
WANG YUANHAO (CN)
CHEN XIUMEI (CN)
HUANG WEI (CN)
SUN XIANQIANG (CN)
YU YANG (CN)
HUANG JUNHONG (CN)
LIU WEI (CN)
CHEN XINDE (CN)
HE HU (CN)
ZHONG WENGE (CN)
WANG YUANHAO (CN)
CHEN XIUMEI (CN)
HUANG WEI (CN)
SUN XIANQIANG (CN)
YU YANG (CN)
HUANG JUNHONG (CN)
LIU WEI (CN)
CHEN XINDE (CN)
Application Number:
PCT/CN2022/080313
Publication Date:
September 14, 2023
Filing Date:
March 11, 2022
Export Citation:
Assignee:
QILU REGOR THERAPEUTICS INC (CN)
International Classes:
C07D401/12; A61K31/4985; A61P35/00; C07D401/14; C07D403/12; C07D405/14; C07D417/12; C07D471/04; C07D487/04; C07D491/048; C07D513/04; C07F1/00
Domestic Patent References:
| WO2020157652A2 | 2020-08-06 | |||
| WO2009085185A1 | 2009-07-09 | |||
| WO2006056399A2 | 2006-06-01 | |||
| WO2004005281A1 | 2004-01-15 | |||
| WO2003037347A1 | 2003-05-08 | |||
| WO2003099771A2 | 2003-12-04 | |||
| WO2004046120A2 | 2004-06-03 | |||
| WO2000009495A1 | 2000-02-24 | |||
| WO2005028444A1 | 2005-03-31 | |||
| WO2004080980A1 | 2004-09-23 | |||
| WO2004056786A2 | 2004-07-08 | |||
| WO2003024967A2 | 2003-03-27 | |||
| WO2001064655A1 | 2001-09-07 | |||
| WO2000053595A1 | 2000-09-14 | |||
| WO2001014402A1 | 2001-03-01 | |||
| WO2009085185A1 | 2009-07-09 | |||
| WO2012129344A1 | 2012-09-27 | |||
| WO2011101409A1 | 2011-08-25 | |||
| WO2003062236A1 | 2003-07-31 | |||
| WO2010075074A1 | 2010-07-01 | |||
| WO2012061156A1 | 2012-05-10 |
Foreign References:
| US5521184A | 1996-05-28 | |||
| USPP60578491P |
Other References:
HENLEY, S. A.F. A. DICK, CELL DIV, vol. 7, no. 1, 2012, pages 10
EKHOLM, S. V.S. I. REED, CURR OPIN CELL BIOL, vol. 12, no. 6, 2000, pages 676 - 84
XU, X. ET AL., BIOCHEMISTRY, vol. 38, no. 27, 1999, pages 8713 - 22
KEYOMARSI, K. ET AL., N ENGL J MED, vol. 347, no. 20, 2002, pages 1566 - 75
NAKAYAMA, N. ET AL., CANCER, vol. 116, no. 11, 2010, pages 2621 - 34
AU-YEUNG, G. ET AL., CLIN CANCER RES, vol. 23, no. 7, 2017, pages 1862 - 1874
ROSEN, D. G. ET AL., CANCER, vol. 106, no. 9, 2006, pages 1925 - 32
SCALTRITI, M. ET AL., PROC NATL ACAD SCI USA, vol. 108, no. 9, 2011, pages 3761 - 6
HERRERA-ABREU, M. T. ET AL., CANCER RES, vol. 76, no. 8, 2016, pages 2301 - 13
CHEN, Y N. ET AL., PROC NATL ACAD SCI USA, vol. 96, no. 8, 1999, pages 4325 - 9
MENDOZA, N. ET AL., CANCER RES, vol. 63, no. 5, 2003, pages 1020 - 4
CICENAS, J. ET AL., CANCERS, vol. 6, no. 4, 2014, pages 2224 - 42
S. M. BERGE ET AL., J. PHARM. SCI., vol. 66, 1977, pages 1 - 19
SMITH, ROGER M.: "Chromatographic Science Series", vol. 75, 1998, LOUGHBOROUGH UNIVERSITY, article "Supercritical Fluid Chromatography with Packed Columns", pages: 223 - 249
FINNINMORGAN, J. PHARM. SCI., vol. 88, 1999, pages 955 - 958
HOOVER, JOHN E.: "Remington's Pharmaceutical Sciences", 1975, MACK PUBLISHING CO.
"Pharmaceutical Dosage Forms", 1980, MARCEL DECKER
THOMAS SORRELL: "Handbook of Pharmaceutical Excipients", 1999, AMERICAN PHARMACEUTICAL ASSOCIATION
MOLENAAR ET AL., PROC NATL ACAD SCI USA, vol. 106, no. 31, pages 12968 - 12973
HU, S. ET AL., MOL CANCER THER, vol. 14, no. 11, 2015, pages 2576 - 85
TAKADA ET AL., CANCER RES, vol. 77, no. 18, 2017, pages 4881 - 4893
GOODMANGILMAN: "The Pharmacological Basis of Therapeutics", 1996, MEDICAL ECONOMICS COMPANY
"Handbook of Chemistry and Physics", article "Periodic Table of the Elements"
GREENE: "Comprehensive Organic Transformations: A Guide to Functional Group Preparations", vol. 1-12, 1991, LAROCK, JOHN WILEY AND SONS
EKHOLM, S. V.S. I. REED, CURR OPIN CELL BIOL, vol. 12, no. 6, 2000, pages 676 - 84
XU, X. ET AL., BIOCHEMISTRY, vol. 38, no. 27, 1999, pages 8713 - 22
KEYOMARSI, K. ET AL., N ENGL J MED, vol. 347, no. 20, 2002, pages 1566 - 75
NAKAYAMA, N. ET AL., CANCER, vol. 116, no. 11, 2010, pages 2621 - 34
AU-YEUNG, G. ET AL., CLIN CANCER RES, vol. 23, no. 7, 2017, pages 1862 - 1874
ROSEN, D. G. ET AL., CANCER, vol. 106, no. 9, 2006, pages 1925 - 32
SCALTRITI, M. ET AL., PROC NATL ACAD SCI USA, vol. 108, no. 9, 2011, pages 3761 - 6
HERRERA-ABREU, M. T. ET AL., CANCER RES, vol. 76, no. 8, 2016, pages 2301 - 13
CHEN, Y N. ET AL., PROC NATL ACAD SCI USA, vol. 96, no. 8, 1999, pages 4325 - 9
MENDOZA, N. ET AL., CANCER RES, vol. 63, no. 5, 2003, pages 1020 - 4
CICENAS, J. ET AL., CANCERS, vol. 6, no. 4, 2014, pages 2224 - 42
S. M. BERGE ET AL., J. PHARM. SCI., vol. 66, 1977, pages 1 - 19
SMITH, ROGER M.: "Chromatographic Science Series", vol. 75, 1998, LOUGHBOROUGH UNIVERSITY, article "Supercritical Fluid Chromatography with Packed Columns", pages: 223 - 249
FINNINMORGAN, J. PHARM. SCI., vol. 88, 1999, pages 955 - 958
HOOVER, JOHN E.: "Remington's Pharmaceutical Sciences", 1975, MACK PUBLISHING CO.
"Pharmaceutical Dosage Forms", 1980, MARCEL DECKER
THOMAS SORRELL: "Handbook of Pharmaceutical Excipients", 1999, AMERICAN PHARMACEUTICAL ASSOCIATION
MOLENAAR ET AL., PROC NATL ACAD SCI USA, vol. 106, no. 31, pages 12968 - 12973
HU, S. ET AL., MOL CANCER THER, vol. 14, no. 11, 2015, pages 2576 - 85
TAKADA ET AL., CANCER RES, vol. 77, no. 18, 2017, pages 4881 - 4893
GOODMANGILMAN: "The Pharmacological Basis of Therapeutics", 1996, MEDICAL ECONOMICS COMPANY
"Handbook of Chemistry and Physics", article "Periodic Table of the Elements"
GREENE: "Comprehensive Organic Transformations: A Guide to Functional Group Preparations", vol. 1-12, 1991, LAROCK, JOHN WILEY AND SONS
Attorney, Agent or Firm:
LIU, SHEN & ASSOCIATES (CN)
Download PDF: